The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

The trial is designed to assess the therapy's efficacy when administered subcutaneously in single ascending doses.

Implementing LGBTQ+ inclusive language in patient care and clinical trials for dermatology could improve data accuracy, ...